Literature DB >> 7510743

Sensitivity of human leukemia cells in exponential or stationary growth phase to anti-CD5 immunotoxins. Role of intracellular processing events.

R Chignola1, C Anselmi, A Franceschi, M Pasti, C Candiani, G Tridente, M Colombatti.   

Abstract

We have assayed the sensitivity of Jurkat cells in different growth phases to an anti-CD5-ricin A chain (ST.1-RTA) immunotoxins (IT). Jurkat cells proliferated exponentially until a stationary growth phase was reached. Proliferating and stationary cells displayed marked differences in sensitivity to ST.1-RTA treatment; the time required to kill one log of target cells (T10) was 70 h in proliferating and 12 h in stationary cells, respectively. Differences in sensitivity to IT treatment were greatly diminished by the addition of the IT enhancer monensin (T10 = 4.9 and 3.5 h in proliferating and stationary cells, respectively). Binding and internalization studies carried out with fluoresceinated ST.1 mAb revealed that the higher sensitivity of stationary cells to ST.1-RTA treatment was not due to an increased uptake or to faster internalization kinetics of IT molecules in this cell population; rather, our data indicated that a different intracellular routing of IT molecules took place in the two cell populations. Mathematical modeling of experimental data allowed us to calculate the efficiency of the intracellular transport of IT molecules toward a subcellular compartment facilitating toxin translocation to the cell cytosol. The IT intracellular processing in stationary cells was 5.5-fold more efficient than in proliferating cells. This value strictly correlated with the higher sensitivity of the stationary cell population to ST.1-RTA treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510743

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.

Authors:  D Castelletti; G Fracasso; S Righetti; G Tridente; R Schnell; A Engert; M Colombatti
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

2.  Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies.

Authors:  R Chignola; T Cestari; C Guerriero; A P Riviera; S Ferrari; A Brendolan; M Gobbo; S Amato; S Sartoris; G Fracasso; M G Liuzzi; P Riccio; G Tridente; G Andrighetto
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

3.  In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin.

Authors:  S E Gasanov; E D Rael; N E Gasanov; L P Vernon
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

4.  Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response.

Authors:  Silvia Sartoris; Maria G Testi; Elisabetta Stefani; Roberto Chignola; Chiara Guerriero; Andrea Matucci; Tiziana Cestari; Aldo Scarpa; Anna P Riviera; Giovanna Zanoni; Giuseppe Tridente; Giancarlo Andrighetto
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

5.  Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.

Authors:  Marta Mazzocco; Matteo Martini; Antonio Rosato; Elisabetta Stefani; Andrea Matucci; Silvia Dalla Santa; Francesco De Sanctis; Stefano Ugel; Sara Sandri; Giovanna Ferrarini; Tiziana Cestari; Sergio Ferrari; Paola Zanovello; Vincenzo Bronte; Silvia Sartoris
Journal:  Immunology       Date:  2015-06-15       Impact factor: 7.397

6.  Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin.

Authors:  R Chignola; R Foroni; A Franceschi; M Pasti; C Candiani; C Anselmi; G Fracasso; G Tridente; M Colombatti
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.